Paul Cacciatore
Paul Cacciatore campaign leader

UK NICE Fails To Support Avastin For Recurrent Advanced Ovarian Cancer

The UK's National Institute for Health and Clinical Excellence (NICE) published draft guidance ( today that fails to support the use of bevacizumab (Avastin) for treating recurrent advanced ovarian cancer, which has returned six months or more after initial treatment with platinum-based chemotherapy (i.e., platinum-sensitive disease).

to comment